Similar articles

• BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.

  Palma M, Ristori E, Ricevuto E, Giannini G, Gulino A. Palma M, et al. Crit Rev Oncol Hematol. 2006 Jan;57(1):1-23. doi: 10.1016/j.critrevonc.2005.05.003. Epub 2005 Dec 6. Crit Rev Oncol Hematol. 2006. PMID: 16337408 Review.
• [Clinicopathological characteristics of familial breast cancer].

  Kamimura M, Takei H, Suemasu K. Kamimura M, et al. Nihon Rinsho. 2007 Jun 28;65 Suppl 6:607-9. Nihon Rinsho. 2007. PMID: 17682217 Review. Japanese. No abstract available.
• Cancer risk assessment at the atomic level.

  Monteiro AN, Couch FJ. Monteiro AN, et al. Cancer Res. 2006 Feb 15;66(4):1897-9. doi: 10.1158/0008-5472.CAN-05-3034. Cancer Res. 2006. PMID: 16488985
• Structure-based assessment of BRCA1 and BRCA2 mutations in a small Spanish population.

  Salgado J, Zabalegui N, García-Amigot F, Gil MC, González MS, García-Foncillas J. Salgado J, et al. Oncol Rep. 2005 Jul;14(1):85-8. Oncol Rep. 2005. PMID: 15944772
• [Hereditary/familial breast cancer].

  Fukutomi T. Fukutomi T. Nihon Rinsho. 2007 Jun 28;65 Suppl 6:245-8. Nihon Rinsho. 2007. PMID: 17682162 Review. Japanese. No abstract available.